BMS Gains Second Indication For Krazati – One More Than Amgen’s Lumakras
CRC Added To NSCLC, Both Second-Line Or Later
Bristol Myers Squibb won US FDA approval in colorectal cancer for the KRAS G12C inhibitor from its $4.8bn Mirati buy, but Amgen’s first-to-market product still has a big commercial lead.
